Cascadian Therapeutics, Inc. (CASC2)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Scott D. Myers
Employees:
3101 WESTERN AVE., SUITE 600, SEATTLE, WA 98121
(206) 801-2100

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company, engages in the development of therapeutic products for the treatment of cancer. Its lead product candidate ONT-380, is an orally active and selective small-molecule HER2 inhibitor. It also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Seattle, WA.

Data derived from most recent annual or quarterly report
Market Cap 0 Shares Outstanding0 Avg 30-day Volume 638.417 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.3
Price to Revenue0.0 Debt to Equity0.0 EBITDA-55.984 Million
Price to Book Value1.8771 Operating Margin0.0 Enterprise Value103.686 Million
Current Ratio8.065 EPS Growth0.613 Quick Ratio7.962
1 Yr BETA 0.8167 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-36.0731 Altman Z-Score2.4222 Free Cash Flow to Firm -37.158 Million
View SEC Filings from CASC2 instead.

View recent insider trading info

Funds Holding CASC2 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CASC2 BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2018-02-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2018-01-31:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-12-07:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
  • 8-K: filed on 2017-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-06-09:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-03-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-03-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-02-03:
    Item 1.02: Termination of a Material Definitive Agreement
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BARRIS PETER J

    • 10% Owner
    No longer subject to file 2018-03-09 0

    LOVE TED W

    • Director
    No longer subject to file 2018-03-09 0

    MOTT DAVID M

    • 10% Owner
    No longer subject to file 2018-03-09 0

    MAKOWER JOSHUA

    • 10% Owner
    No longer subject to file 2018-03-09 0

    SANDELL SCOTT D

    • 10% Owner
    No longer subject to file 2018-03-09 0

    SPIEGELMAN DANIEL K

    • Director
    No longer subject to file 2018-03-09 0

    HENNEY CHRISTOPHER S

    • Director
    No longer subject to file 2018-03-09 0

    JAMES STEVEN P

    • Director
    No longer subject to file 2018-03-09 0

    BASKETT FOREST

    • 10% Owner
    No longer subject to file 2018-03-09 0

    MYERS SCOTT DUNSETH PRESIDENT AND CEO

    • Officer
    • Director
    No longer subject to file 2018-03-09 0

    CHRISTIANSON GARY CHIEF OPERATING OFFICER

    • Officer
    No longer subject to file 2018-03-09 0

    VISWANATHAN RAVI

    • 10% Owner
    No longer subject to file 2018-03-09 0

    EASTLAND JULIA MARIE CFO & CBO

    • Officer
    No longer subject to file 2018-03-09 0

    FYFE GWEN A.

    • Director
    No longer subject to file 2018-03-09 0

    SONSINI PETER W.

    • 10% Owner
    No longer subject to file 2018-03-09 0

    FLORENCE ANTHONY A. JR.

    • 10% Owner
    No longer subject to file 2018-03-09 0

    PETERSON SCOTT ROBERT CHIEF SCIENTIFIC OFFICER

    • Officer
    No longer subject to file 2018-03-09 0

    SAKODA JON

    • 10% Owner
    No longer subject to file 2018-03-09 0

    GROWTH EQUITY OPPORTUNITIES IV, LLC

    NEW ENTERPRISE ASSOCIATES 15, L.P.

    NEA PARTNERS 15, L.P.

    NEA 15 GP, LLC

    • 10% Owner
    No longer subject to file 2018-03-09 0

    AZELBY ROBERT

    • Director
    No longer subject to file 2018-03-09 0

    WALKER LUKE NATHANIEL SVP, CLINICAL DEVELOPMENT

    • Officer
    No longer subject to file 2018-03-09 0

    JACKSON RICHARD L.

    • Director
    11,968 2016-12-31 0

    LAMPERT MARK N

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF INC/IL

    • Director
    • 10% Owner
    18,799,368 2016-06-23 0

    KIRKMAN ROBERT L PRESIDENT & CEO

    • Officer
    • Director
    0 2015-09-24 0

    HAUSMAN DIANA CHIEF MEDICAL OFFICER

    • Officer
    0 2015-09-24 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    No longer subject to file 2015-02-05 0

    VENKATESAN JAY EVP AND GENERAL MANAGER

    • Officer
    0 2014-12-16 0

    STOUGHTON W. VICKERY

    • Director
    46,692 2014-06-06 0

    WILLIAMS DOUGLAS E

    • Director
    0 2013-06-13 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    INVESTMENT 10 LLC

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    7,837,978 2013-06-04 0

    AYER CAPITAL MANAGEMENT, LP

    • 10% Owner
    No longer subject to file 2011-06-23 0

    AYER CAPITAL MANAGEMENT, LP

    AYER CAPITAL PARTNERS, LLC

    ACM CAPITAL PARTNERS, LLC

    VENKATESAN JAY

    • 10% Owner
    3,126,188 2011-05-21 0

    KARAN SHASHI K. CORPORATE CONTROLLER

    • Officer
    10,100 2010-09-28 0

    BURLEY STEPHEN

    • Director
    0 2008-06-04 0

    KIRKPATRICK LYNN CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2008-06-04 0

    TAYLOR EDWARD A. CFO, VP FIN & ADMIN, SEC

    • Officer
    0 2008-06-04 0

    BLAIR S. ROBERT

    • Director
    9,876 2007-12-10 0

    WELSH MICHAEL C.

    • Director
    21,886 2007-12-10 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments